Ludmila Shostakovich-Koretskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ludmila Shostakovich-Koretskaya has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- O. P. Schevchenko-Makarenko
ДЗ «Дніпропетровська медична академія МОЗ України
6 shared publications - Kateryna Y. Lytvyn
Dnipro State Medical University
5 shared publications Weijing He
Veterans Administration Research Center for AIDS and HIV-1 Infection, South Texas Veterans Health Care System, San Antonio, TX 78229; Center for Personalized Medicine, South Texas Veterans Health Care System, San Antonio, TX 78229; Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229
4 shared publications- I. V. Budayeva
Dnipro State Medical University, Dnipro, Ukraine
3 shared publications - Sunil K. Ahuja
Veterans Administration Research Center for AIDS and HIV-1 Infection, South Texas Veterans Healthcare System, USA
3 shared publications V. D. Tkachenko
ME Dnipropetrovsk Municipal Clin Hosp 21, Kanatnaya Str 17, UA-49006 Dnipro, Ukraine
3 shared publications
Latest Publications
- Open Access
- 30 May 2026
- Published by Publishing House Zaslavsky in CHILD`S HEALTH
- Vol. 21 (3) , 131-136
Linear IgA-bullous dermatosis: a retrospective clinical case series with a proposed diagnostic algorithm in children and adults
Background. Linear IgA bullous dermatosis (LABD) is a rare autoimmune subepidermal vesiculobullous disease affecting both children and adults and frequently mimicking infectious or allergic dermatoses. In clinical infectious disease practice, LABD may be misdiagnosed as varicella, recurrent herpes zoster, drug-induced toxicoderma, and other autoimmune bullous dermatoses. The purpose was to provide a pragmatic diagnostic algorithm for differentiating infectious and autoimmune vesiculobullous diseases based on an analysis of own clinical case series and up‑to‑date evidence, with an emphasis on accessible diagnostic steps under limited resources. Materials and methods. This study is a retrospective clinical case series including 5 patients with clinically established LABD (two children aged 3 and 5; three adults aged 19, 25, and 27 years). All participants underwent clinical examination, basic laboratory tests; if indicated, polymerase chain reaction of vesicle contents for varicella zoster virus (VZV) and herpes simplex virus (HSV) 1/2 DNA to exclude the infectious nature of the disease. Based on the analysis of the literature and our own data, modern approaches to clinical morphological and immunopathological verification of LABD (biopsy + direct (DIF)/indirect immunofluorescence, linear IgA) were summarized. The report was prepared in accordance with the CARE 2013 and STROBE guidelines. Results. In 4 of 5 cases, a potential trigger occurred 1–3 months before onset (acute respiratory viral infection or lacunar tonsillitis; nonsteroidal anti-inflammatory drugs/paracetamol use). Fever or systemic toxicity was absent in all patients. Lesions were polymorphic with annular/arciform clusters (“string of pearls”), with moderate pruritus in 4 of 5 cases. Mucosal involvement was not observed, except erosive cheilitis in one child. We propose a stepwise diagnostic algorithm prioritizing exclusion of VZV/HSV infection before prescription of immunosuppressive drugs and emphasizing DIF as the diagnostic gold standard. Conclusions. LABD remains a multidisciplinary diagnostic challenge. In conditions of limited availability of immunopathological verification of the disease, it is advisable to use a structured algorithm: 1) assessment of clinical morphology of rashes and possible triggers; 2) exclusion of herpesvirus infections (VZV/HSV) in bullous rashes; 3) consultation with a dermatologist; 4) referral for biopsy with DIF; 5) assessment of severity; 6) individualized selection of therapy taking into account severity and safety.
- 30 May 2026
- Published by Publishing House Zaslavsky in CHILD`S HEALTH
- Vol. 21 (3) , 131-136
Open AccessLinear IgA-bullous dermatosis: a retrospective clinical case series with a proposed diagnostic algorithm in children and adults
Background. Linear IgA bullous dermatosis (LABD) is a rare autoimmune subepidermal vesiculobullous disease affecting both children and adults and frequently mimicking infectious or allergic dermatoses. In clinical infectious disease practice, LABD may be misdiagnosed as varicella, recurrent herpes zoster, drug-induced toxicoderma, and other autoimmune bullous dermatoses. The purpose was to provide a pragmatic diagnostic algorithm for differentiating infectious and autoimmune vesiculobullous diseases based on an analysis of own clinical case series and up‑to‑date evidence, with an emphasis on accessible diagnostic steps under limited resources. Materials and methods. This study is a retrospective clinical case series including 5 patients with clinically established LABD (two children aged 3 and 5; three adults aged 19, 25, and 27 years). All participants underwent clinical examination, basic laboratory tests; if indicated, polymerase chain reaction of vesicle contents for varicella zoster virus (VZV) and herpes simplex virus (HSV) 1/2 DNA to exclude the infectious nature of the disease. Based on the analysis of the literature and our own data, modern approaches to clinical morphological and immunopathological verification of LABD (biopsy + direct (DIF)/indirect immunofluorescence, linear IgA) were summarized. The report was prepared in accordance with the CARE 2013 and STROBE guidelines. Results. In 4 of 5 cases, a potential trigger occurred 1–3 months before onset (acute respiratory viral infection or lacunar tonsillitis; nonsteroidal anti-inflammatory drugs/paracetamol use). Fever or systemic toxicity was absent in all patients. Lesions were polymorphic with annular/arciform clusters (“string of pearls”), with moderate pruritus in 4 of 5 cases. Mucosal involvement was not observed, except erosive cheilitis in one child. We propose a stepwise diagnostic algorithm prioritizing exclusion of VZV/HSV infection before prescription of immunosuppressive drugs and emphasizing DIF as the diagnostic gold standard. Conclusions. LABD remains a multidisciplinary diagnostic challenge. In conditions of limited availability of immunopathological verification of the disease, it is advisable to use a structured algorithm: 1) assessment of clinical morphology of rashes and possible triggers; 2) exclusion of herpesvirus infections (VZV/HSV) in bullous rashes; 3) consultation with a dermatologist; 4) referral for biopsy with DIF; 5) assessment of severity; 6) individualized selection of therapy taking into account severity and safety.
- Open Access
- 27 May 2026
- Published by Professional Event, LLC
- No. 2,p. 45-49
Linear IgA Bullous Dermatosis as a Subject of Differential Diagnosis with VZV Infection in Routine Medical Practice
Linear IgA bullous dermatosis (LABD) is a rare disease that can occur in both children and adults. The epidemiological prevalence of the disease is 0.2–2.3 per 1 million population per year and reveals two age categories of patients: children under 5 years of age and patients over 60 years. The disease is characterized by a genetic predisposition connected to certain types of leukocyte antigen (HLA): HLA-B8, HLA-DR3, HLA-DQ2 and HLA-cw7. However, the causes of the disease have not been fully elucidated. There is an assumption that this dermatosis is one of the variants of Dühring’s dermatitis herpetiformis. According to the literature, the disease develops more frequently at the background of malignant processes, and in childhood – often after an acute respiratory infection. Given that LABD is a rare dermatosis, its diagnosis requires a comprehensive clinical and laboratory examination. A clinical case. A 3-year-old child was referred to the Department of Infectious Diseases of the Dnipro State Medical University for consultation. According to the obtained data, it became evident that 5–6 weeks after a mild form of acute respiratory infection with bronchitis, a dermatologist diagnosed the patient with chronic recurrent varicella-zoster virus (VZV) infection, namely, herpes zoster, and acyclovir was prescribed for this reason. However, acyclovir therapy over 6 months period did not result in a positive therapeutic effect. Considering the long course of the disease, the absence of a positive effect from acyclovir, the next step in patient management was a consultation with an infectious disease specialist. Based on the lack of therapeutic effect of acyclovir and visual features of the exanthema, which is not typical for herpes zoster, an alternative diagnosis of autoimmune vesiculobullous dermatosis was considered. To reliably exclude VZV infection, a polymerase chain reaction (PCR) test for VZV DNA in the vesicle fluid obtained by scarification was performed. The test result was negative. Light microscopy of the subepidermal blister (scarification) was also performed, and neutrophilic infiltration on the papillae of the dermis with single acantholytic cells were found. The obtained data confirmed diagnosis of LABD. Oral prednisolone therapy at a dose of 1 mg/kg/day for 14 days had a positive effect, a rapid regression of the elements of the vesicular necklace was observed, new elements of the rash did not appear. After the rash disappeared, complete epithelization of the skin occurred. Conclusions. The diagnosis of LABD requires a comprehensive clinical and laboratory assessment. Prior to initiation of the immunosuppressive therapy, it is advisable to test for VZV DNA PCR in the vesicular fluid to exclude possible VZV infection. It is advisable to use systemic glucocorticosteroids, cytostatics or sulfone drugs in the treatment. Based on author’s experience of differential diagnostic for the causes of vesiculobullous dermatoses made an algorithm for differential diagnosis between VZV infections and LABD was proposed.
- 27 May 2026
- Published by Professional Event, LLC
- No. 2,p. 45-49
Open AccessLinear IgA Bullous Dermatosis as a Subject of Differential Diagnosis with VZV Infection in Routine Medical Practice
Linear IgA bullous dermatosis (LABD) is a rare disease that can occur in both children and adults. The epidemiological prevalence of the disease is 0.2–2.3 per 1 million population per year and reveals two age categories of patients: children under 5 years of age and patients over 60 years. The disease is characterized by a genetic predisposition connected to certain types of leukocyte antigen (HLA): HLA-B8, HLA-DR3, HLA-DQ2 and HLA-cw7. However, the causes of the disease have not been fully elucidated. There is an assumption that this dermatosis is one of the variants of Dühring’s dermatitis herpetiformis. According to the literature, the disease develops more frequently at the background of malignant processes, and in childhood – often after an acute respiratory infection. Given that LABD is a rare dermatosis, its diagnosis requires a comprehensive clinical and laboratory examination. A clinical case. A 3-year-old child was referred to the Department of Infectious Diseases of the Dnipro State Medical University for consultation. According to the obtained data, it became evident that 5–6 weeks after a mild form of acute respiratory infection with bronchitis, a dermatologist diagnosed the patient with chronic recurrent varicella-zoster virus (VZV) infection, namely, herpes zoster, and acyclovir was prescribed for this reason. However, acyclovir therapy over 6 months period did not result in a positive therapeutic effect. Considering the long course of the disease, the absence of a positive effect from acyclovir, the next step in patient management was a consultation with an infectious disease specialist. Based on the lack of therapeutic effect of acyclovir and visual features of the exanthema, which is not typical for herpes zoster, an alternative diagnosis of autoimmune vesiculobullous dermatosis was considered. To reliably exclude VZV infection, a polymerase chain reaction (PCR) test for VZV DNA in the vesicle fluid obtained by scarification was performed. The test result was negative. Light microscopy of the subepidermal blister (scarification) was also performed, and neutrophilic infiltration on the papillae of the dermis with single acantholytic cells were found. The obtained data confirmed diagnosis of LABD. Oral prednisolone therapy at a dose of 1 mg/kg/day for 14 days had a positive effect, a rapid regression of the elements of the vesicular necklace was observed, new elements of the rash did not appear. After the rash disappeared, complete epithelization of the skin occurred. Conclusions. The diagnosis of LABD requires a comprehensive clinical and laboratory assessment. Prior to initiation of the immunosuppressive therapy, it is advisable to test for VZV DNA PCR in the vesicular fluid to exclude possible VZV infection. It is advisable to use systemic glucocorticosteroids, cytostatics or sulfone drugs in the treatment. Based on author’s experience of differential diagnostic for the causes of vesiculobullous dermatoses made an algorithm for differential diagnosis between VZV infections and LABD was proposed.
- Open Access
- 20 April 2026
- Published by Ternopil State Medical University in Інфекційні хвороби
- No. 1,p. 69-75
SARS-COV-2 VARIANT EVOLUTION: GLOBAL PATTERNS, NEW SUBVARIANTS, AND REGIONAL CONTEXT (UKRAINE & HIV)
Since late 2019, SARS-CoV-2 has diversified into numerous lineages, driving recurrent global waves of COVID-19. This narrative review synthesizes evidence on the evolutionary dynamics of SARS-CoV-2 with emphasis on Omicron subvariants, including JN.1 and its descendants, and emerging 2025 lineages (Nimbus and Stratus). We summarize major mechanisms shaping viral diversification – mutation/antigenic drift, recombination, and prolonged infection in immunocompromised hosts (including people living with HIV) – that can promote stepwise accumulation of immune-escape mutations. The review covers literature and genomic surveillance reports from 2019–2025 (WHO resources, GISAID, outbreak.info, PubMed/Scopus) and focuses on mutation profiles of key variants, global prevalence trends, and Ukraine-specific context. A dedicated section addresses why Ukraine – despite a relatively high HIV burden in Eastern Europe – has not been recognized as a major source of globally dominant variants of concern. Contributing factors discussed include limited sequencing coverage, reduced travel/export potential, expansion of ART, and stochastic and structural determinants required for widespread dissemination of newly arising lineages.We conclude that ongoing immune escape remains likely, underscoring the need for robust genomic surveillance, timely vaccine/therapeutic updates, and integration of COVID-19 monitoring with HIV services.
- 20 April 2026
- Published by Ternopil State Medical University in Інфекційні хвороби
- No. 1,p. 69-75
Open AccessSARS-COV-2 VARIANT EVOLUTION: GLOBAL PATTERNS, NEW SUBVARIANTS, AND REGIONAL CONTEXT (UKRAINE & HIV)
Since late 2019, SARS-CoV-2 has diversified into numerous lineages, driving recurrent global waves of COVID-19. This narrative review synthesizes evidence on the evolutionary dynamics of SARS-CoV-2 with emphasis on Omicron subvariants, including JN.1 and its descendants, and emerging 2025 lineages (Nimbus and Stratus). We summarize major mechanisms shaping viral diversification – mutation/antigenic drift, recombination, and prolonged infection in immunocompromised hosts (including people living with HIV) – that can promote stepwise accumulation of immune-escape mutations. The review covers literature and genomic surveillance reports from 2019–2025 (WHO resources, GISAID, outbreak.info, PubMed/Scopus) and focuses on mutation profiles of key variants, global prevalence trends, and Ukraine-specific context. A dedicated section addresses why Ukraine – despite a relatively high HIV burden in Eastern Europe – has not been recognized as a major source of globally dominant variants of concern. Contributing factors discussed include limited sequencing coverage, reduced travel/export potential, expansion of ART, and stochastic and structural determinants required for widespread dissemination of newly arising lineages.We conclude that ongoing immune escape remains likely, underscoring the need for robust genomic surveillance, timely vaccine/therapeutic updates, and integration of COVID-19 monitoring with HIV services.
- Open Access
- 26 March 2026
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 1,p. 27-35
Associations of Class II DRB1 Locus Alleles with Susceptibility of HIV-Infected Patients to Tuberculosis and other Respiratory Infections
Objective — to investigate the association of HLA DRB1 gene polymorphisms with the risks of HIV-associated tuberculosis and recurrent bacterial respiratory tract infections, considering patient sex. Materials and methods. A prospective study of 116 HIV-infected patients with clinical stages II—IV of HIV infection was conducted. The patients were divided into three groups: those with tuberculosis (n = 35), those with recurrent bacterial respiratory tract infections (n = 39) and those with other infections (mycoses, chronic HSV infection, toxoplasmosis etc.) (n = 42). We studied the association between the presence of DRB1 gene alleles in HIV-infected patients and the likelihood of developing certain comorbid infections, including tuberculosis and recurrent bacterial respiratory tract infections. Results and discussion. Associations were found between certain loci and opportunistic infections associated with tuberculosis and recurrent bacterial respiratory tract infections. Not all DRB1 locus alleles are significantly associated with opportunistic diseases. In HIV-infected patients, the presence of the DRB1*03, DRB1*13 and DRB1 *16 alleles is statistically significantly associated with the likelihood of occurrence or relative resistance to some opportunistic infections (p < 0,05). The analysis of the effect of sex on the occurrence of some opportunistic infections showed that men with the DRB1*13 allele were more likely to have both recurrent bacterial respiratory tract infections (25.0 %) and tuberculosis (29.2 %) (p < 0,05). This explains why men are more likely to develop tuberculosis and die more often than women. Conclusions. The study identified important genetic markers that can be used to predict the risks of developing tuberculosis and other respiratory infections in HIV-infected patients, which will contribute to better treatment and prevention strategies. Susceptibility to tuberculosis is associated with the presence of the DRB1*03 (22.9 %) and DRB1*13 (31.4 %) alleles. These alleles increase the risk of developing tuberculosis in HIV-infected individuals. The DRB1*13 allele (25.6 %) is also associated with the frequency of recurrent bacterial respiratory tract infections. Carriers of the DRB1*16 allele (frequency of detection 19.0 %) had a lower risk of developing tuberculosis (11.4 %) and recurrent bacterial respiratory tract infections (12.8 %), which may indicate a protective effect of this allele. Sex differences were found in carriers of these loci and the development of tuberculosis and other respiratory infections. In women with the DRB1*03 allele, the probability of developing tuberculosis was 45.5 %, which significantly exceeded the frequency of other infections (3.8 %, p < 0.01). In men with the DRB1*13 allele, both recurrent bacterial respiratory tract infections (25.0 %) and tuberculosis (29.2 %) were more often detected. Male carriers of the DRB1*11 were less susceptible to tuberculosis (16.7 %, p = 0.06), which may indicate a protective role of this allele.
- 26 March 2026
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 1,p. 27-35
Open AccessAssociations of Class II DRB1 Locus Alleles with Susceptibility of HIV-Infected Patients to Tuberculosis and other Respiratory Infections
Objective — to investigate the association of HLA DRB1 gene polymorphisms with the risks of HIV-associated tuberculosis and recurrent bacterial respiratory tract infections, considering patient sex. Materials and methods. A prospective study of 116 HIV-infected patients with clinical stages II—IV of HIV infection was conducted. The patients were divided into three groups: those with tuberculosis (n = 35), those with recurrent bacterial respiratory tract infections (n = 39) and those with other infections (mycoses, chronic HSV infection, toxoplasmosis etc.) (n = 42). We studied the association between the presence of DRB1 gene alleles in HIV-infected patients and the likelihood of developing certain comorbid infections, including tuberculosis and recurrent bacterial respiratory tract infections. Results and discussion. Associations were found between certain loci and opportunistic infections associated with tuberculosis and recurrent bacterial respiratory tract infections. Not all DRB1 locus alleles are significantly associated with opportunistic diseases. In HIV-infected patients, the presence of the DRB1*03, DRB1*13 and DRB1 *16 alleles is statistically significantly associated with the likelihood of occurrence or relative resistance to some opportunistic infections (p < 0,05). The analysis of the effect of sex on the occurrence of some opportunistic infections showed that men with the DRB1*13 allele were more likely to have both recurrent bacterial respiratory tract infections (25.0 %) and tuberculosis (29.2 %) (p < 0,05). This explains why men are more likely to develop tuberculosis and die more often than women. Conclusions. The study identified important genetic markers that can be used to predict the risks of developing tuberculosis and other respiratory infections in HIV-infected patients, which will contribute to better treatment and prevention strategies. Susceptibility to tuberculosis is associated with the presence of the DRB1*03 (22.9 %) and DRB1*13 (31.4 %) alleles. These alleles increase the risk of developing tuberculosis in HIV-infected individuals. The DRB1*13 allele (25.6 %) is also associated with the frequency of recurrent bacterial respiratory tract infections. Carriers of the DRB1*16 allele (frequency of detection 19.0 %) had a lower risk of developing tuberculosis (11.4 %) and recurrent bacterial respiratory tract infections (12.8 %), which may indicate a protective effect of this allele. Sex differences were found in carriers of these loci and the development of tuberculosis and other respiratory infections. In women with the DRB1*03 allele, the probability of developing tuberculosis was 45.5 %, which significantly exceeded the frequency of other infections (3.8 %, p < 0.01). In men with the DRB1*13 allele, both recurrent bacterial respiratory tract infections (25.0 %) and tuberculosis (29.2 %) were more often detected. Male carriers of the DRB1*11 were less susceptible to tuberculosis (16.7 %, p = 0.06), which may indicate a protective role of this allele.
- Open Access
- 27 June 2025
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 31 (2) , 33-39
A case of actinomycosis of the maxillary sinus in an immunocompetent patient: clinical and morphological aspects
The article provides a detailed description of a clinical case of actinomycosis of the maxillary sinus in a 40-year-old woman without immune disorders. The described case demonstrates the need for a diagnostic search for actinomycosis in cases of prolonged sinusitis of the paranasal sinuses in the absence of effect from local and systemic treatment (including antibiotic therapy), as well as the value of the pathohistological method of studying the material for verifying the diagnosis. Analysis of this case of actinomycosis of the maxillary sinus suggests that it may improve the management of rare infections.
- 27 June 2025
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 31 (2) , 33-39
Open AccessA case of actinomycosis of the maxillary sinus in an immunocompetent patient: clinical and morphological aspects
The article provides a detailed description of a clinical case of actinomycosis of the maxillary sinus in a 40-year-old woman without immune disorders. The described case demonstrates the need for a diagnostic search for actinomycosis in cases of prolonged sinusitis of the paranasal sinuses in the absence of effect from local and systemic treatment (including antibiotic therapy), as well as the value of the pathohistological method of studying the material for verifying the diagnosis. Analysis of this case of actinomycosis of the maxillary sinus suggests that it may improve the management of rare infections.
- Open Access
- 19 June 2025
- Published by Ternopil State Medical University in Медична освіта
- No. 1,p. 99-107
ВИКОРИСТАННЯ ШТУЧНОГО ІНТЕЛЕКТУ В КЛІНІЧНІЙ МЕДИЦИНІ Й НАУКОВИХ ДОСЛІДЖЕННЯХ
Анотація. У статті проаналізовано можливості й перспективи впровадження штучного інтелекту (ШІ) в клінічну практику України, зокрема у сферу медичних досліджень та освіти в умовах воєнного стану. Використано приклади з українських клінік та освітніх установ, що вже застосовують або тестують ШІ-інструменти. Особливу увагу приділено комунікації між пацієнтом і лікарем, автоматизації діагностики, моніторингу й аналізу даних. Надано рекомендації для інтеграції ШІ в систему охорони здоров’я з дотриманням етичних, юридичних і безпекових стандартів.
- 19 June 2025
- Published by Ternopil State Medical University in Медична освіта
- No. 1,p. 99-107
Open AccessВИКОРИСТАННЯ ШТУЧНОГО ІНТЕЛЕКТУ В КЛІНІЧНІЙ МЕДИЦИНІ Й НАУКОВИХ ДОСЛІДЖЕННЯХ
Анотація. У статті проаналізовано можливості й перспективи впровадження штучного інтелекту (ШІ) в клінічну практику України, зокрема у сферу медичних досліджень та освіти в умовах воєнного стану. Використано приклади з українських клінік та освітніх установ, що вже застосовують або тестують ШІ-інструменти. Особливу увагу приділено комунікації між пацієнтом і лікарем, автоматизації діагностики, моніторингу й аналізу даних. Надано рекомендації для інтеграції ШІ в систему охорони здоров’я з дотриманням етичних, юридичних і безпекових стандартів.
- Open Access
- 4 June 2025
- Published by Ternopil State Medical University in Інфекційні хвороби
- No. 2,p. 71-77
ЗАСТОСУВАННЯ ШТУЧНОГО ІНТЕЛЕКТУ В КЛІНІЧНІЙ МЕДИЦИНІ, НАУКОВИХ ДОСЛІДЖЕННЯХ ТА ОСВІТІ В УМОВАХ ВОЄННОГО СТАНУ
Проаналізовано можливості та перспективи впровадження штучного інтелекту (ШІ) в клінічну практику України, зокрема у сферу медичних досліджень та освіти в умовах воєнного стану. Використано приклади з українських клінік та освітніх установ, що вже застосовують або тестують ШІ-інструменти. Особливу увагу приділено комунікації між пацієнтом і лікарем, автоматизації діагностики, моніторингу та аналізу даних. Запропоновано рекомендації для інтеграції ШІ в систему охорони здоров’я з дотриманням етичних, юридичних і безпекових стандартів.
- 4 June 2025
- Published by Ternopil State Medical University in Інфекційні хвороби
- No. 2,p. 71-77
Open AccessЗАСТОСУВАННЯ ШТУЧНОГО ІНТЕЛЕКТУ В КЛІНІЧНІЙ МЕДИЦИНІ, НАУКОВИХ ДОСЛІДЖЕННЯХ ТА ОСВІТІ В УМОВАХ ВОЄННОГО СТАНУ
Проаналізовано можливості та перспективи впровадження штучного інтелекту (ШІ) в клінічну практику України, зокрема у сферу медичних досліджень та освіти в умовах воєнного стану. Використано приклади з українських клінік та освітніх установ, що вже застосовують або тестують ШІ-інструменти. Особливу увагу приділено комунікації між пацієнтом і лікарем, автоматизації діагностики, моніторингу та аналізу даних. Запропоновано рекомендації для інтеграції ШІ в систему охорони здоров’я з дотриманням етичних, юридичних і безпекових стандартів.
- Open Access
- 21 May 2024
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 2,p. 22-26
Impact of Antiretroviral Therapy on the Progression of EBV-Associated Lymphomas
Objective — to determine the impact of antiretroviral therapy (ART) on the progression of lymphomas induced by Epstein—Barr virus (EBV) in patients infected with human immunodeficiency virus (HIV). Materials and methods. We analysed clinical-epidemiological, laboratory and serological indicators of 57 HIV-infected patients with clinically and laboratory-confirmed EBV co-infection. Patients were divided into two groups: the primary group consisted of 9 patients with lymphomas (66.7 % of whom received ART without concurrent chemotherapy with cytostatic antitumor agents, while the rest did not receive ART), and the control group included 48 patients without neoplasms. Results and discussion. To assess the effectiveness of ART in treating EBV-induced lymphomas, we analysed the general clinical, immunological and virological indicators of patients at the start of observation and after 6 months of therapy. In patients with EBV-associated lymphomas receiving ART, there was an increase in CD4+ lymphocytes, a decrease in HIV viral load, an increase in hemoglobin levels (p < 0.05), and a significant reduction in EBV viral load (p < 0.01). In patients with EBV-associated lymphomas who did not receive ART, there was a further decrease in CD4+ lymphocytes and an increase in EBV viral load. Two clinical cases are presented: in one, a patient received palliative chemotherapy according to the CHOP regimen but did not receive ART due to an absolute refusal because of poor drug tolerance; in the other case, the patient received ART without cytostatic antitumor drugs due to an absolute refusal. Conclusions. The study results established that the use of ART in patients with EBV-associated lymphomas not only improved the primary indicators characteristic of HIV but also significantly reduced the EBV viral load (p < 0.01). The dynamics of the main immunological and virological indicators in patients with EBV-associated lymphomas who did not receive ART were negative, as evidenced by the further decrease in CD4+ lymphocytes and an increase in EBV viral load. From the clinical cases presented, it can be concluded that the timely administration of ART to patients with EBV-associated lymphomas is a crucial therapeutic tool that not only facilitates positive immunological and virological changes in HIV infection but also affects the quality and duration of life in patients with EBV-associated lymphomas.
- 21 May 2024
- Published by Publishing Company VIT-A-POL in Tuberculosis, Lung Diseases, HIV Infection
- No. 2,p. 22-26
Open AccessImpact of Antiretroviral Therapy on the Progression of EBV-Associated Lymphomas
Objective — to determine the impact of antiretroviral therapy (ART) on the progression of lymphomas induced by Epstein—Barr virus (EBV) in patients infected with human immunodeficiency virus (HIV). Materials and methods. We analysed clinical-epidemiological, laboratory and serological indicators of 57 HIV-infected patients with clinically and laboratory-confirmed EBV co-infection. Patients were divided into two groups: the primary group consisted of 9 patients with lymphomas (66.7 % of whom received ART without concurrent chemotherapy with cytostatic antitumor agents, while the rest did not receive ART), and the control group included 48 patients without neoplasms. Results and discussion. To assess the effectiveness of ART in treating EBV-induced lymphomas, we analysed the general clinical, immunological and virological indicators of patients at the start of observation and after 6 months of therapy. In patients with EBV-associated lymphomas receiving ART, there was an increase in CD4+ lymphocytes, a decrease in HIV viral load, an increase in hemoglobin levels (p < 0.05), and a significant reduction in EBV viral load (p < 0.01). In patients with EBV-associated lymphomas who did not receive ART, there was a further decrease in CD4+ lymphocytes and an increase in EBV viral load. Two clinical cases are presented: in one, a patient received palliative chemotherapy according to the CHOP regimen but did not receive ART due to an absolute refusal because of poor drug tolerance; in the other case, the patient received ART without cytostatic antitumor drugs due to an absolute refusal. Conclusions. The study results established that the use of ART in patients with EBV-associated lymphomas not only improved the primary indicators characteristic of HIV but also significantly reduced the EBV viral load (p < 0.01). The dynamics of the main immunological and virological indicators in patients with EBV-associated lymphomas who did not receive ART were negative, as evidenced by the further decrease in CD4+ lymphocytes and an increase in EBV viral load. From the clinical cases presented, it can be concluded that the timely administration of ART to patients with EBV-associated lymphomas is a crucial therapeutic tool that not only facilitates positive immunological and virological changes in HIV infection but also affects the quality and duration of life in patients with EBV-associated lymphomas.
- 1 January 2024
- Published by MedCrave Group Kft. in MOJ Public Health
- Vol. 13 (3) , 187-189
Emerging trends in pediatric viral hepatitis: Case studies and insights
Background: Viral hepatitis is a leading cause of liver disease in children, primarily caused by hepatitis A, B, and C viruses.1,2 Since 2022, there has been a rising number of pediatric hepatitis cases with unclear origins, indicating the potential emergence of new etiologies.3 This study aimed to analyze the increasing trends of viral hepatitis in children, with a particular focus on hepatitis C. It included data from a regional hospital registry in Dnipro, Ukraine, that documented 167 children diagnosed with viral hepatitis C and B, highlighting the challenges of diagnosis and treatment. Additionally, the study presents illustrative cases to demonstrate clinical variability and systemic barriers, offering a comprehensive overview of the issue.4,5 Methods: A retrospective analysis of clinical and laboratory data from 167 children aged 2–18 years with viral hepatitis was conducted. Barriers to care, treatment outcomes, and the utility of direct-acting antiviral (DAA) therapies were assessed. Three illustrative cases were presented to highlight the diverse clinical challenges and outcomes.6 Results: In a study of 167 children, 86% were diagnosed with chronic hepatitis C (CHC), and 14% with chronic hepatitis B (CHBV). Of the 106 treated for CHC with direct-acting antiviral agents (DAA), 105 achieved a sustained virologic response (SVR) within 12 weeks. All 16 patients treated for CHBV, using pegylated interferons, entecavir, or lamivudine, reached undetectable DNA levels or significant viral load reductions, with normalized ALT and AST levels. Barriers to care included low public awareness, high diagnostic costs, and logistical delays. Three case studies highlight challenges such as severe acute hepatitis, chronic infections, and unknown causes.7,8 Conclusion: Addressing gaps in awareness, diagnostic processes, and access to pediatric-appropriate medications is critical for improving outcomes in pediatric hepatitis. Continued research is needed to address the rising burden of acute hepatitis cases of unknown etiology.9,10
- 1 January 2024
- Published by MedCrave Group Kft. in MOJ Public Health
- Vol. 13 (3) , 187-189
Emerging trends in pediatric viral hepatitis: Case studies and insights
Background: Viral hepatitis is a leading cause of liver disease in children, primarily caused by hepatitis A, B, and C viruses.1,2 Since 2022, there has been a rising number of pediatric hepatitis cases with unclear origins, indicating the potential emergence of new etiologies.3 This study aimed to analyze the increasing trends of viral hepatitis in children, with a particular focus on hepatitis C. It included data from a regional hospital registry in Dnipro, Ukraine, that documented 167 children diagnosed with viral hepatitis C and B, highlighting the challenges of diagnosis and treatment. Additionally, the study presents illustrative cases to demonstrate clinical variability and systemic barriers, offering a comprehensive overview of the issue.4,5 Methods: A retrospective analysis of clinical and laboratory data from 167 children aged 2–18 years with viral hepatitis was conducted. Barriers to care, treatment outcomes, and the utility of direct-acting antiviral (DAA) therapies were assessed. Three illustrative cases were presented to highlight the diverse clinical challenges and outcomes.6 Results: In a study of 167 children, 86% were diagnosed with chronic hepatitis C (CHC), and 14% with chronic hepatitis B (CHBV). Of the 106 treated for CHC with direct-acting antiviral agents (DAA), 105 achieved a sustained virologic response (SVR) within 12 weeks. All 16 patients treated for CHBV, using pegylated interferons, entecavir, or lamivudine, reached undetectable DNA levels or significant viral load reductions, with normalized ALT and AST levels. Barriers to care included low public awareness, high diagnostic costs, and logistical delays. Three case studies highlight challenges such as severe acute hepatitis, chronic infections, and unknown causes.7,8 Conclusion: Addressing gaps in awareness, diagnostic processes, and access to pediatric-appropriate medications is critical for improving outcomes in pediatric hepatitis. Continued research is needed to address the rising burden of acute hepatitis cases of unknown etiology.9,10
- Open Access
- 11 June 2022
- Published by Ternopil State Medical University in Інфекційні хвороби
- No. 1,p. 24-39
ПАТОГЕНЕТИЧНА РОЛЬ ЕНДОТОКСИКОЗУ В РОЗВИТКУ ТЯЖКИХ ФОРМ COVID-19: КЛІНІКО-ПАТОМОРФОЛОГІЧНЕ ДОСЛІДЖЕННЯ
Мета роботи – на підставі клініко-морфологічного дослідження особливостей уражень легень і шлунково-кишкового тракту на різних стадіях запального процесу обґрунтувати гіпотезу ендотоксикозу як ключового патогенетичного фактора системної ендотеліальної дисфункції і вторинного ураження легень при COVID-19. Матеріали і методи. Дослідження базується на клініко-патоморфологічному вивченні 52 випадків смерті від COVID-19, з яких для ретельного гістологічного дослідження був відібранний аутопсійний матеріал від 18 померлих. У частині випадків був задіяний імерсійний метод мікроскопії, виконували імуногістохімічне дослідження. Результати. Основним проявом альтеративного фактора розвитку дифузного альвеолярного пошкодження (ДАП) був мікротромбоз на фоні лейкоцитарних пасток, що формувались нетозом гіперактивованих поліморфноядерних лейкоцитів. Встановили відсутність ознак попереднього запального процесу і ознак міграції лейкоцитів через стінки капілярів у просвіт альвеол. Одночасно гістологічна картина змін в тонкій кишці відповідала гострому десквамативно-ерозивному запальному процесу вірусно-бактерійної етіології з ознаками активної транслокації ендотоксину. В запальному інфільтраті слизової оболонки тонкої кишки формувались гіперергічні вогнищеві лімфоїдні інфільтрати, як в стадії ранньої ексудації (p<0,005), так і в стадії проліферації ДАП (p<0,001). Продемонстровано достовірно низький показник імунорегуляторного індексу (ІРІ) CD4/CD8 у гістологічних зразках запального інфільтрату легень порівняно з ІРІ у запальному інфільтраті тонкої кишки (p<0,001). Запропоновано модель патогенезу COVID-19, згідно з якою ураження легень може виникати вторинно, за механізмом гепатопульмонального синдрому. Висновки. Є підстави вважати, що вхідними воротами для збудника при тяжкому перебігу COVID-19, поряд з дихальною системою, є слизова оболонка дистальних відділів тонкої кишки. Виявлені морфологічні прояви тяжкої ендотеліальної дисфункції з пошкодженням ендотелію свідчать більше про ураження ендотоксином за механізмом параалергічної реакції, а не про пряме вірусне ураження.
- 11 June 2022
- Published by Ternopil State Medical University in Інфекційні хвороби
- No. 1,p. 24-39
Open AccessПАТОГЕНЕТИЧНА РОЛЬ ЕНДОТОКСИКОЗУ В РОЗВИТКУ ТЯЖКИХ ФОРМ COVID-19: КЛІНІКО-ПАТОМОРФОЛОГІЧНЕ ДОСЛІДЖЕННЯ
Мета роботи – на підставі клініко-морфологічного дослідження особливостей уражень легень і шлунково-кишкового тракту на різних стадіях запального процесу обґрунтувати гіпотезу ендотоксикозу як ключового патогенетичного фактора системної ендотеліальної дисфункції і вторинного ураження легень при COVID-19. Матеріали і методи. Дослідження базується на клініко-патоморфологічному вивченні 52 випадків смерті від COVID-19, з яких для ретельного гістологічного дослідження був відібранний аутопсійний матеріал від 18 померлих. У частині випадків був задіяний імерсійний метод мікроскопії, виконували імуногістохімічне дослідження. Результати. Основним проявом альтеративного фактора розвитку дифузного альвеолярного пошкодження (ДАП) був мікротромбоз на фоні лейкоцитарних пасток, що формувались нетозом гіперактивованих поліморфноядерних лейкоцитів. Встановили відсутність ознак попереднього запального процесу і ознак міграції лейкоцитів через стінки капілярів у просвіт альвеол. Одночасно гістологічна картина змін в тонкій кишці відповідала гострому десквамативно-ерозивному запальному процесу вірусно-бактерійної етіології з ознаками активної транслокації ендотоксину. В запальному інфільтраті слизової оболонки тонкої кишки формувались гіперергічні вогнищеві лімфоїдні інфільтрати, як в стадії ранньої ексудації (p<0,005), так і в стадії проліферації ДАП (p<0,001). Продемонстровано достовірно низький показник імунорегуляторного індексу (ІРІ) CD4/CD8 у гістологічних зразках запального інфільтрату легень порівняно з ІРІ у запальному інфільтраті тонкої кишки (p<0,001). Запропоновано модель патогенезу COVID-19, згідно з якою ураження легень може виникати вторинно, за механізмом гепатопульмонального синдрому. Висновки. Є підстави вважати, що вхідними воротами для збудника при тяжкому перебігу COVID-19, поряд з дихальною системою, є слизова оболонка дистальних відділів тонкої кишки. Виявлені морфологічні прояви тяжкої ендотеліальної дисфункції з пошкодженням ендотелію свідчать більше про ураження ендотоксином за механізмом параалергічної реакції, а не про пряме вірусне ураження.